Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 662

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19

Open access
Levin, Myron J., Ustianowski, Andrew, De Wit, Stéphane, Launay, Odile, Avila, Miles, Templeton, Alison, Yuan, Yuan, Seegobin, Seth, Ellery, Adam, Levinson, Dennis J., Ambery, Philip, Arends, Rosalinda H., Beavon, Rohini, Dey, Kanika, Garbes, Pedro, Kelly, Elizabeth J., Koh, Gavin C.K.W., Near, Karen A., Padilla, Kelly W., Psachoulia, Konstantina, Sharbaugh, Audrey, Streicher, Katie, Pangalos, Menelas N., Esser, Mark T.·2022·New England Journal of Medicine

Abstract

BACKGROUND: The monoclonal-antibody combination AZD7442 is composed of tixagevimab and cilgavimab, two neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that have an extended half-life and have been shown to have prophylactic and therapeutic effects in animal models. Pharmacokinetic data in humans indicate that AZD7442 has an extended half-life of approximately 90 days. METHODS: In an ongoing phase 3 trial, we enrolled adults (≥18 years of age) who had an increased risk of an inadequate response to vaccination against coronavirus disease 2019 (Covid-19), an increased risk of exposure to SARS-CoV-2, or both. Participants were randomly assigned in a 2:1 ratio to receive a single dose (two consecutive intramuscular injections, one containing tixagevimab and the other containing cilgavimab) of either 300 mg of AZD7442 or saline placebo, and they were followed for up to 183 days in the primary analysis. The primary safety end point was the incidence of adverse events after a single dose of AZD7442. The primary efficacy end point was symptomatic Covid-19 (SARS-CoV-2 infection confirmed by means of reverse-transcriptase-polymerase-chain-reaction assay) occurring after administration of AZD7442 or placebo and on or before day 183. RESULTS: A total of 5197 participants underwent randomization and received one dose of AZD7442 or placebo (3460 in the AZD7442 group and 1737 in the placebo group). The primary analysis was conducted after 30% of the participants had become aware of their randomized assignment. In total, 1221 of 3461 participants (35.3%) in the AZD7442 group and 593 of 1736 participants (34.2%) in the placebo group reported having at least one adverse event, most of which were mild or moderate in severity. Symptomatic Covid-19 occurred in 8 of 3441 participants (0.2%) in the AZD7442 group and in 17 of 1731 participants (1.0%) in the placebo group (relative risk reduction, 76.7%; 95% confidence interval [CI], 46.0 to 90.0; P<0.001); extended follow-up at a median of 6 months showed a relative risk reduction of 82.8% (95% CI, 65.8 to 91.4). Five cases of severe or critical Covid-19 and two Covid-19-related deaths occurred, all in the placebo group. CONCLUSIONS: A single dose of AZD7442 had efficacy for the prevention of Covid-19, without evident safety concerns. (Funded by AstraZeneca and the U.S. government; PROVENT ClinicalTrials.gov number, NCT04625725.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa2116620

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 30 references

Cited by

See all 662

Metadata

Authors
Levin, M. J., Ustianowski, A., De Wit, S., Launay, O., Avila, M., Templeton, A., Yuan, Y., Seegobin, S., Ellery, A., Levinson, D. J., Ambery, P., Arends, R. H., Beavon, R., Dey, K., Garbes, P., Kelly, E. J., Koh, G. C. K. W., Near, K. A., Padilla, K. W., Psachoulia, K., Sharbaugh, A., Streicher, K., Pangalos, M. N., & Esser, M. T.
Venue
New England Journal of Medicine
Published
2022-06-09
Volume
386
Issue
23
Pages
2188-2200
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W4224289402
Cited by
662
References
30
FWCI
70.88
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19. https://app.cochat.ai/papers/10.1056/nejmoa2116620
The paper
Levin, M. J., Ustianowski, A., De Wit, S., Launay, O., Avila, M., Templeton, A., Yuan, Y., Seegobin, S., Ellery, A., Levinson, D. J., Ambery, P., Arends, R. H., Beavon, R., Dey, K., Garbes, P., Kelly, E. J., Koh, G. C. K. W., Near, K. A., Padilla, K. W., . . . Esser, M. T. (2022). Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2116620

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.